Stocks · News reference
Gainers Doximity (NYSE:DOCS) stock rose 85.1% to $38.25 during Friday's pre-market session. The market value of their outstanding shares is at $3.7 billion. As per the news, the Q1 earnings report came out
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Ardelyx announced results from a real-world analysis presented at the American Society of Nephrology (ASN) Kidney Week 2026, demonstrating serum phosphate reductions in dialysis patients treated with XPHOZAH.
A securities class action has been filed against Ardelyx, Inc. (NASDAQ: ARDX) alleging the company misled investors about its commercial performance and growth prospects for its drug products IBSRELA and XPHOZAH. The lawsuit covers purchases between January 13, 2025 and August 6, 2026. On August 6, 2026, Ardelyx reduced its full-year 2026 IBSRELA revenue guidance and withdrew long-term XPHOZAH guidance due to increased payer access barriers, causing the stock to drop 18% in one day from $4.87 to $4.00 per share.
Ardelyx, Inc. (NASDAQ:ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced results from
A securities class action lawsuit has been filed against Ardelyx, Inc. for allegedly providing misleading statements about its commercial performance while concealing material adverse facts regarding payer access barriers and reimbursement issues for XPHOZAH and IBSRELA. The company reduced its 2026 IBSRELA revenue guidance and withdrew long-term XPHOZAH guidance on August 6, 2026, causing the stock to decline approximately 18% in a single day.
On September 24, 2026, Creative Medical Technology Holdings, Inc. (the "Company") entered into a Stock Purchase Agreement (the "Purchase Agreement") with Creative Acquisition Corp. ("CAC"),